A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors Meeting Abstract
| Authors: | Drilon, A. E.; Johnson, M. L.; Gadgeel, S. M.; Nepert, D.; Feng, G.; Golmakani, M.; Reddy, M.; Harney, A.; Oliver, C.; Mills, B.; Therond, J.; Rothenberg, S. M.; Sharma, M.; Yap, T. A. |
| Abstract Title: | A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.3020 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 3020 -- This meeting was also held virtually -- Source: Cinahl |
